PTC Therapeutics to acquire ST-920 gene therapy for Fabry disease from Sangamo for $111M upfront

PTC THERAPEUTICS, INC.

Upfront $111M plus up to $100M milestones: $80M on FDA accelerated approval, $20M on full approval of ST-920 BLA.
ST-920 is a one-time AAV gene therapy candidate for Fabry disease, acquired from Sangamo in bankruptcy auction.
Closing subject to Bankruptcy Court approval (hearing Sept 10, 2026) and HSR waiting period; deadline Oct 15, 2026.
PTC was selected as winning bidder in Sangamo's Chapter 11 case; agreement includes customary reps/warranties, no indemnification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.